Market cap
$751 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -- | -- | -- |
| Net Profit | -36.48 | -116.56 | -3.10 | -41.22 | -179.01 |
| EPS | -36.36 | -77.41 | -30.51 | -202.28 | -209.08 |
| Book Value | -- | -- | 329.73 | 197.87 | 70.93 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -57.61 | -59.51 | -13.28 | -14.22 | -51.42 |
| Return on Capital
| -57.59 | -59.49 | -- | -14.21 | -51.42 |
| Return on Assets
| -47.14 | -50.44 | -10.97 | -13.65 | -46.09 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.00 | -- |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
--
|
-14.21
|
-51.42
|
-107.13
|
-72.28
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-13.28
Higher than Peers by 27.12
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
-13.28
|
-14.22
|
-51.42
|
-107.19
|
-72.30
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-10.97
Higher than Peers by 20.00
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
-10.97
|
-13.65
|
-46.09
|
-81.69
|
-62.19
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
--
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
--
|
--
|
-277.86
|
20.26
|
-15.44
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-3.10
Higher than Peers by 4.20
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
-3.10
|
11.99
|
-85.50
|
19.94
|
-15.59
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
-30.51
Lower than Peers by 45.16
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
-30.51
|
-0.51
|
-1.41
|
0.30
|
-0.12
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
105.35
Higher than Peers by 115.53
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
105.35
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
--
|
0.00
|
--
|
--
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
--
|
--
|
--
|
--
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
33.56
Higher than Peers by 27.75
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
33.56
|
51.35
|
11.47
|
4.17
|
4.21
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
33.56
Higher than Peers by 27.86
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
33.56
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
--
|
--
|
--
|
--
|
-496.11
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
--
|
-31.86
|
-16.21
|
-0.60
|
-2.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
5.85
Higher than Peers by 0.67
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
5.85
|
3.17
|
4.59
|
0.91
|
3.04
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-2.42
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
-2.42
|
-21.63
|
-12.35
|
0.26
|
-1.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
751
Higher than Peers by 605
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
|
751
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|